Mapping the N6-methyladenosine (m6A) transcriptome in prostate cancer has established its clinical potential value as a prognostic biomarker for this disease. A multidisciplinary approach that integrates genomics, transcriptomics, epitranscriptomics, proteomics and clinical oncology is essential to translate the intricacies of m6A modification into tangible benefits for patients.
Scientific Data — MethAgingDB: a comprehensive DNA methylation database for aging biology. MethAgingDB includes 93 datasets, with 11,474 profiles from 13 distinct human tissues and 1,361 profiles from 9 distinct mouse tissues. The database provides preprocessed DNA methylation data in a consistent matrix format, along with tissue-specific DMSs and DMRs, gene-centric aging insights, and an extensive collection of epigenetic clocks. Together, MethAgingDB is expected to streamline aging-related epigenetic research and support the development of robust, biologically informed aging biomarkers.
Colon cancer remains a major global health concern, ranking third among the most diagnosed cancers and the leading cause of cancer-related death worldwide. One critical factor that makes treating colon cancer challenging is the presence of cancer stem cells.
Though typically present in small populations, these powerful cells drive tumor growth, resist standard treatments, and often contribute to relapse. They achieve this through their “stemness,” a set of properties that enable these cells to self-renew and differentiate into other cell types. Thus, understanding how stemness might be controlled at the molecular level is essential for developing effective therapies for colon cancer.
Over the past two decades, researchers have identified several key molecules involved in both the development of the colon and the progression of colon cancer. Among them are CDX1 and CDX2, two homeobox transcription factors that help establish and maintain the identity of intestinal epithelial cells.
Researchers from Cornell and Northwestern universities have developed a rapid, cell-free method for building nanoparticle vaccines that mimic viruses at the molecular level, offering a powerful new tool for responding to emerging pandemics.
By producing and folding full-length viral membrane proteins directly into synthetic lipid bubbles called liposomes, the technique creates vaccine candidates in hours, rather than weeks or months, and could pave the way for faster, more adaptable immunization strategies against deadly viruses like Nipah.
The research, presented in the paper “Cell-Free Expression of Nipah Virus Transmembrane Proteins for Proteoliposome Vaccine Design,” was published in the journal ACS Nano.
